Citadel Advisors’s Genomic Health, Inc. GHDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q2 | – | Sell |
-3,400
| Closed | -$238K | – | 10256 |
|
|
2019
Q1 | $238K | Sell |
3,400
-600
| -15% | -$44.5K | ﹤0.01% | 7956 |
|
|
2018
Q4 | $258K | Sell |
4,000
-4,000
| -50% | -$280K | ﹤0.01% | 7503 |
|
|
2018
Q3 | $562K | Sell |
8,000
-4,700
| -37% | -$275K | ﹤0.01% | 6514 |
|
|
2018
Q2 | $640K | Buy |
+12,700
| New | +$504K | ﹤0.01% | 5979 |
|
|
2016
Q1 | – | Sell |
-1,200
| Closed | -$42K | – | 8563 |
|
|
2015
Q4 | $42K | Sell |
1,200
-2,100
| -64% | -$56.2K | ﹤0.01% | 7450 |
|
|
2015
Q3 | $70K | Buy |
3,300
+2,200
| +200% | +$56.7K | ﹤0.01% | 7308 |
|
|
2015
Q2 | $31K | Buy |
1,100
+100
| +10% | +$2.82K | ﹤0.01% | 7949 |
|
|
2015
Q1 | $31K | Sell |
1,000
-700
| -41% | -$22.3K | ﹤0.01% | 7686 |
|
|
2014
Q4 | $54K | Sell |
1,700
-2,300
| -58% | -$74.9K | ﹤0.01% | 7141 |
|
|
2014
Q3 | $113K | Sell |
4,000
-1,200
| -23% | -$33.5K | ﹤0.01% | 6298 |
|
|
2014
Q2 | $142K | Sell |
5,200
-1,800
| -26% | -$47.9K | ﹤0.01% | 5913 |
|
|
2014
Q1 | $184K | Buy |
7,000
+600
| +9% | +$17.2K | ﹤0.01% | 5600 |
|
|
2013
Q4 | $187K | Sell |
6,400
-400
| -6% | -$12.7K | ﹤0.01% | 5095 |
|
|
2013
Q3 | $208K | Sell |
6,800
-2,300
| -25% | -$76.9K | ﹤0.01% | 4724 |
|
|
2013
Q2 | $289K | Buy |
+9,100
| New | +$299K | ﹤0.01% | 4332 |
|
Citadel Advisors's GHDX Position: Q3 2019 in Review
Citadel Advisors sold out of Genomic Health, Inc. (GHDX) in Q3 2019, closing a stake of 291,969 shares — an estimated $20.1M sold.
Citadel Advisors first reported a position in GHDX in Q2 2013 and held it in 24 quarters. The position peaked at $24.9M in Q1 2019. 221 funds tracked by Wall St. Rank hold GHDX as of Q3 2019.
- Citadel Advisors reported no remaining Genomic Health, Inc. position as of Q3 2019 after selling out during the quarter.
- Citadel Advisors sold 291,969 Genomic Health, Inc. shares in Q3 2019, an estimated $20.1M.
- Citadel Advisors first reported a position in Genomic Health, Inc. in Q2 2013 and held it in 24 quarters.
- Citadel Advisors's Genomic Health, Inc. position peaked at $24.9M in Q1 2019.
- 221 funds tracked by Wall St. Rank held Genomic Health, Inc. as of Q3 2019.
Based on Citadel Advisors's 13F filing for Q3 2019, filed 14 Nov 2019.